These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2107173)

  • 1. von Willebrand disease.
    Miller JL
    Hematol Oncol Clin North Am; 1990 Feb; 4(1):107-28. PubMed ID: 2107173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Von Willebrand's disease. Clinical picture, diagnosis, and treatment.
    Bowie EJ
    Clin Lab Med; 1984 Jun; 4(2):303-17. PubMed ID: 6209061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of von Willebrand's disease.
    Logan LJ
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1079-94. PubMed ID: 1400073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports].
    Kleinschmidt S; Fuchs-Buder T; Wilhelm W; Seyfert UT; Mörsdorf S
    Anaesthesist; 2002 Oct; 51(10):825-34. PubMed ID: 12395174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin?
    Favaloro EJ
    Semin Thromb Hemost; 2008 Feb; 34(1):113-27. PubMed ID: 18393148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inborn and acquired von Willebrand disease].
    Schneppenheim R; Budde U
    Hamostaseologie; 2008 Dec; 28(5):312-9. PubMed ID: 19132162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The factor VIII/von Willebrand factor complex: basic and clinical issues.
    Federici AB
    Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U; Metzner HJ; Müller HG
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of von Willebrand's Disease.
    Mannucci PM
    N Engl J Med; 2004 Aug; 351(7):683-94. PubMed ID: 15306670
    [No Abstract]   [Full Text] [Related]  

  • 17. Interaction of the von Willebrand factor with platelets and thrombosis.
    Perutelli P; Mori PG
    Recenti Prog Med; 1997 Nov; 88(11):526-9. PubMed ID: 9401429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor.
    Turecek PL; Siekmann J; Schwarz HP
    Semin Thromb Hemost; 2002 Apr; 28(2):149-60. PubMed ID: 11992238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.
    Michiels JJ; Budde U; van der Planken M; van Vliet HH; Schroyens W; Berneman Z
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):401-36. PubMed ID: 11686107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.